Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.
Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs
